STOCK TITAN

MapLight Therapeutics (MPLT) SEC Filings

MPLT NASDAQ

This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.

In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.

For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.

Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.

EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

MapLight Therapeutics, Inc. (MPLT) was the issuer in an amendment reporting T. Rowe Price Investment Management, Inc.’s beneficial ownership of 945,216 common shares, equal to 1.7% of the class as of September 30, 2026. The reporting person listed sole voting power over 938,725 shares and sole dispositive power over 945,216 shares, with no shared voting or dispositive power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
ownership
-
Rhea-AI Summary

MapLight Therapeutics, Inc. entered into a sales agreement with Leerink Partners LLC under which MapLight may sell voting common stock with an aggregate offering price of up to $100,000,000. Sales, if any, may be made in transactions deemed “at the market offerings.”

Leerink will use commercially reasonable efforts to sell shares based on MapLight’s instructions and is entitled to a commission of up to 3.0% of the aggregate gross sales price per share sold. MapLight is not obligated to sell shares and may suspend offers or terminate the agreement at any time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
current report
Rhea-AI Summary

MapLight Therapeutics, Inc. (MPLT) filed a shelf registration statement that, once effective and with an accompanying prospectus supplement, would allow it to offer up to $400,000,000 in aggregate securities: voting common stock, preferred stock, debt securities and warrants. A separate $100,000,000 common-stock sales-agreement prospectus with Leerink Partners LLC is included within, not added to, the shelf amount. Any unsold portion may be offered under other shelf offerings after termination of the sales agreement.

MapLight intends to use net proceeds for general corporate purposes, including clinical trials, research and development, general and administrative expenses and capital expenditures. It may also use some proceeds for in-licensing, investment in or acquisition of complementary businesses, assets or technologies; it reports no current acquisition plans, commitments or agreements. MapLight said its Phase 2 ZEPHYR schizophrenia trial of ML-007C-MA had positive topline results in July 2026 and that it intends to discuss Phase 3 design with the FDA. It expects VISTA trial topline results in the second half of 2027. After June 2026 topline results from the Phase 2 IRIS trial of ML-004, it intends to discuss next development steps with the FDA for ASD irritability and then evaluate potential collaborations or funding alternatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
registration
-
Rhea-AI Summary

MapLight Therapeutics, Inc. (MPLT) updated its resale registration to cover up to 13,160,261 shares of voting common stock held by selling stockholders. This comprises 9,177,093 shares remaining unsold as of November 1, 2026, and 3,983,168 shares issuable upon exercise of pre-funded warrants. The amendment registers no additional securities. The shares originated in a private placement that closed August 14, 2026, which generated approximately $150.0 million in gross proceeds before placement-agent fees and estimated offering expenses.

MapLight will not receive proceeds from stockholder resales, although it may receive $0.0001 per share if the warrants are exercised for cash. MapLight describes itself as a clinical-stage biopharmaceutical company; its lead candidate is being evaluated in Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis, with VISTA topline results expected in the second half of 2027. The company says substantial public-market sales, or the perception that holders intend to sell, could lower its stock price or increase volatility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
amendment
-
Rhea-AI Summary

MapLight Therapeutics, Inc. (MPLT) is the subject of an amended beneficial-ownership report in which Forbion Growth Opportunities Fund III Cooperatief U.A. reports directly owning 4,428,328 voting common shares. Forbion Growth III Management B.V., as director of the fund, may be deemed to have voting and investment power over those same shares.

Both reporting persons report shared voting and dispositive power over 4,428,328 shares, representing approximately 8.4% of the outstanding voting common stock. The percentage is based on 52,848,208 shares outstanding, as reported in MapLight’s prospectus filed September 23, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
ownership
Rhea-AI Summary

MapLight Therapeutics, Inc. (MPLT) reported a $172.5 million net loss for the nine months ended September 30, 2026, versus $81.6 million a year earlier. Research and development expense was $151.3 million, compared with $73.7 million; operating cash use was $131.7 million versus $91.3 million. Cash, cash equivalents and investments totaled $463.4 million at September 30, and management expects current resources to fund operations through 2028, based on its plans and assumptions.

The company completed an August 2026 private placement that generated approximately $140.1 million in net proceeds after approximately $10.0 million of placement agent fees and offering expenses. In July, it announced positive topline results from ZEPHYR, a Phase 2 trial of lead candidate ML-007C-MA for schizophrenia. MapLight intends to engage the FDA in an end-of-Phase 2 meeting to discuss a confirmatory Phase 3 trial intended, together with ZEPHYR, to support an initial NDA; planning and site identification have begun.

MapLight is also conducting VISTA, a Phase 2 study of ML-007C-MA for Alzheimer's disease psychosis, with topline results expected in the second half of 2027. The company reported no revenue to date from any source, including product sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
quarterly report
-
Rhea-AI Summary

MapLight Therapeutics, Inc. reported third-quarter 2026 results. Cash, cash equivalents and investments were $463.413 million as of September 30, 2026; the company expects these funds to support continued advancement of ML-007C-MA through 2028. It completed a $150 million private placement in August. R&D expenses were $44.208 million versus $27.094 million a year earlier, G&A expenses were $11.135 million versus $4.404 million, and net loss was $51.616 million versus $29.418 million.

Phase 2 ZEPHYR met its primary endpoint: the 210/3 mg twice-daily dose produced a statistically significant and clinically meaningful reduction in PANSS total score versus placebo at Week 5. Start-up activities are underway for planned confirmatory Phase 3 ZEPHYR-2, and MapLight intends to discuss the program with the FDA at an End-of-Phase 2 meeting. Enrollment continues in VISTA for Alzheimer’s disease psychosis; ML-007C-MA has FDA Fast Track designation for that indication. In autism spectrum disorder, Phase 2 IRIS showed clinically meaningful improvement on a prespecified secondary irritability endpoint among adolescents with moderate or greater baseline irritability. MapLight plans FDA discussions on ML-004 and is pausing significant further investment in preclinical and discovery-stage programs beyond near-term milestones, foregoing their advancement into clinical development under its current operating plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
current report
-
Rhea-AI Summary

MapLight Therapeutics, Inc. (MPLT) Chief Discovery Officer Anatol Kreitzer sold 12,248 shares of voting common stock on October 15, 2026, at $7.84 per share. The sale covered statutory tax withholding tied to vesting restricted stock units and was required under the issuer’s equity incentive plans, rather than discretionary. Kreitzer directly held 168,678 shares after the transaction. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.90%
Tags
insider
Rhea-AI Summary

MapLight Therapeutics, Inc. CAO and Interim CFO Jonathan Gillis sold 10,167 shares of Voting Common Stock on October 15, 2026, in a sell-to-cover transaction required by the issuer’s equity incentive plans to fund minimum statutory tax withholding. The reported weighted-average price was $8.08 per share, with transaction prices ranging from $7.755 to $8.3732. Gillis held 142,315 shares directly after the sale. The footnote states the sale was not discretionary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.90%
Tags
insider

FAQ

How many MapLight Therapeutics (MPLT) SEC filings are available on StockTitan?

StockTitan tracks 155 SEC filings for MapLight Therapeutics (MPLT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for MapLight Therapeutics (MPLT)?

The most recent SEC filing for MapLight Therapeutics (MPLT) was filed on November 18, 2026.